What type of study is this?

Combining Ketoacid Analog Supplemented Low-Protein Diets with Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Diabetic Kidney Disease

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study finds lower risks of all-cause and cardiovascular mortality with combined therapy in diabetic kidney disease patients.

Combination therapy significantly reduced all-cause death risk over three years compared to KA-AA alone.
The combination group had lower rates of cardiovascular death, with a hazard ratio of 0.68.
This study involved 1729 adult patients with type 2 diabetes and advanced stages of diabetic kidney disease.
Results indicate that combining SGLT2 inhibitors with a low-protein diet can improve outcomes in diabetic kidney disease.

Yen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study finds lower risks of all-cause and cardiovascular mortality with combined therapy in diabetic kidney disease patients.